Experienced in DICER1 Syndrome

Dr. Aaron J. Scott

Banner-University Medical Group
Tucson, AZ
Experienced
in DICER1 Syndrome
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Aaron Scott is a Hematologist Oncology specialist and a Hematologist in Tucson, Arizona. Dr. Scott and is rated as an Experienced provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Stomach Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Bone Marrow Aspiration. Dr. Scott is currently accepting new patients.

His clinical research consists of co-authoring 56 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Banner - University Medical Center Tucson Campus
Banner-University Medical Center South Campus
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  UnitedHealthcare
  •  Humana

Locations

BANNER-UNIVERSITY MEDICAL GROUP
3838 N Campbell Ave, Bldg 1, Tucson, AZ 85719
520-694-2873

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: ALX148, Cetuximab, Pembrolizumab
Study Phase: Phase 2
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2024
Intervention Type: Drug
Study Drugs: ETC-1922159, Pembrolizumab
Study Phase: Phase 1
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Enrollment Status: Active_not_recruiting
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Nab-paclitaxel, Gemcitabine
Study Phase: Phase 2
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
Enrollment Status: Completed
Publish Date: May 01, 2024
Intervention Type: Other, Dietary supplement
Study Phase: Phase 2
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Enrollment Status: Unknown
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: April 12, 2023
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
An Open-Label, Single-Arm, Two-Stage Phase II Study Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
An Open-Label, Single-Arm, Two-Stage Phase II Study Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: July 15, 2022
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
View 14 Less Clinical Trials

53 Total Publications

The Impact of Bariatric Procedures on the Efficacy of Capecitabine for the Management of Colorectal Cancer.
The Impact of Bariatric Procedures on the Efficacy of Capecitabine for the Management of Colorectal Cancer.
Journal: Obesity surgery
Published: November 30, 2024
Similar Doctors
Expertise in
16
conditions
Dr. Setsuko K. Chambers
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
16
conditions
Dr. Setsuko K. Chambers
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Banner-University Medical Group

3838 N Campbell Ave, 
Tucson, AZ 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Setsuko Chambers is a Gynecologic Oncologist and an Oncologist in Tucson, Arizona. Dr. Chambers and is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Oophorectomy. Dr. Chambers is currently accepting new patients.

Expertise in
14
conditions
Dr. Alejandro R. Recio-Boiles
Hematology | Oncology
Expertise in
14
conditions
Dr. Alejandro R. Recio-Boiles
Hematology | Oncology

Banner-University Medical Group

3838 N Campbell Ave, Bldg 1, 
Tucson, AZ 
520-694-2873
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Alejandro Recio-Boiles is a Hematologist and an Oncologist in Tucson, Arizona. Dr. Recio-Boiles and is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Renal Cell Carcinoma (RCC), Wilms Tumor, Familial Wilms Tumor 2, and Chromophobe Renal Cell Carcinoma. Dr. Recio-Boiles is currently accepting new patients.

Expertise in
11
conditions
Dr. Rachna T. Shroff
Hematology Oncology | Surgical Oncology | Hematology
Expertise in
11
conditions
Dr. Rachna T. Shroff
Hematology Oncology | Surgical Oncology | Hematology

Banner-University Medical Group

3838 N Campbell Ave, Bldg 1, 
Tucson, AZ 
520-694-2873
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachna Shroff is a Hematologist Oncology specialist and a Surgical Oncologist in Tucson, Arizona. Dr. Shroff and is rated as an Elite provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile